Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole vs Ropinirole Ophthalmologic Safety in Early Parkinson's Disease
NCT00144300Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2005
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Expert Panel Overall Assessment of Retinal Deterioration at 2 years. Started Jan 2005; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00144300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144300.